EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020

Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020

GAITHERSBURG, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 20, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full year 2019, recent business developments, financial outlook for full year 2020, and revenue guidance for the first quarter of 2020.

This conference call can be accessed live by telephone or by webcast:

Live Teleconference Information:

Dial in number – toll-free: (855) 766-6521

Dial in number – toll: (262) 912-6157

Conference ID: 7270157
 
Live Webcast Information:

Visit for the live webcast feed.

A replay of the call can be accessed on Emergent’s website under “.”

About Emergent BioSolutions

As a global life sciences company whose mission is to protect and enhance life, we provide solutions that target public health threats. Through our specialty products and services as well as our social responsibility efforts, we aspire to build healthier, safer communities and deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. For more information visit . Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

 

Media Contact:

Lynn Kieffer

Vice President, Corporate Communications

240-631-3391

 



EN
03/02/2020

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manu...

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to be added as the drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax. “We are pleased with the U.S. FDA approval of our sBLA f...

December 12, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approv...

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN® (naloxone HCl) Nasal Spray as the first FDA-approved nasal naloxone spray for emergency treatment of opioid overdose. This historic approval made the life-saving medication easy to administer in both medical and community settings, ultimately l...

November 18, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan fr...

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14 after 19 years of service to the company and its shareholders. “For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent’s mission to protect and save lives,” said Joe Papa, president and CEO of Emergent. “On behalf of the Board and the entire Emergent team, I want to...

November 12, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Emergent BioSolutions Reports Third Quarter 2025 Financial Results Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior yearThird Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38%Raising the Full Year 2025 Revenue and Profitability GuidanceStrong Sequential Naloxone Revenue Growth, Primarily Driven b...

October 29, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Releases New Survey Findings Revealing Heightene...

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting concerns around bioterrorism and the nation’s readiness to respond GAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new survey1 of approximately 250 U.S. policy opinion leaders showing that nearly two-thirds (65 percent) of respondents agree the likelihood of ...

October 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch